Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Molecular Cancer

Yong Li¹  Xin Ye²  Xiaoxu Wei²  Chunwei Li²  Jie Wang²  Yongzhen Mo²  Yunhua Chen²  Ziheng He²  Hui Wang³  Boyao Yu³  Qianjin Liao³  Zhaoyang Zeng³  Yujuan Zhou³  Bo Xiang³  Ming Zhou³  Yuze Hua³  Guiyuan Li³  Wei Xiong³  Daixi Ren³  Xiaoling Li³ 

[1] Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine;Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medical Science, Central South University;NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University;

关键词: Cancer immunotherapy;    Immune checkpoint blockade;    PD-1/PD-L1;    Immune cells;    Precision medicine;   

DOI  :  10.1186/s12943-020-1144-6

来源: DOAJ

【 摘 要 】

Abstract Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a variety of tumors, but resistance during treatment is a major issue. In this review, we describe the utility of PD-L1 expression levels, mutation burden, immune cell infiltration, and immune cell function for predicting the efficacy of PD-1/PD-L1 blockade therapy. Furthermore, we explore the mechanisms underlying immunotherapy resistance caused by PD-L1 expression on tumor cells, T cell dysfunction, and T cell exhaustion. Based on these mechanisms, we propose combination therapeutic strategies. We emphasize the importance of patient-specific treatment plans to reduce the economic burden and prolong the life of patients. The predictive indicators, resistance mechanisms, and combination therapies described in this review provide a basis for improved precision medicine.

【 授权许可】

Unknown